肝癌肝移植手术前后靶向及免疫治疗的指征及时机探讨

李克跃; 魏国微; 黎涛; 王春林; 汤可立; 张毅; 刘延

doi:10.3969/j.issn.1674-7445.2022.05.003

肝癌肝移植手术前后靶向及免疫治疗的指征及时机探讨

doi: 10.3969/j.issn.1674-7445.2022.05.003

550002 贵阳，贵州省人民医院肝胆外科（李克跃、黎涛、王春林、汤可立、张毅、刘延），综合病房（魏国微）

基金项目:

贵州省卫生健康委员会基金 GZWKJ2021-169

详细信息

通讯作者:
李克跃，Email：keyuelee@sohu.com

中图分类号: R617, R735.7
计量
- 文章访问数: 444
- HTML全文浏览量: 223
- PDF下载量: 103
- 被引次数: 0
出版历程
- 收稿日期: 2022-04-16
- 网络出版日期: 2022-09-14
- 刊出日期: 2022-09-15

Discussion on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for hepatocellular carcinoma

Department of Hepatobiliary Surgery, Guizhou Provincial People's Hospital, Guiyang 550002, China

More Information

Corresponding author: Li Keyue, Email: keyuelee@sohu.com

摘要

摘要: 肝移植是治疗早期肝细胞癌（肝癌）的重要措施之一，肝癌肝移植术后复发严重影响了受者的长期生存率。靶向及免疫治疗在降低肝癌分期、控制疾病进展、降低复发率、延长寿命及改善生活质量等方面均发挥了重要作用，然而靶向及免疫治疗在肝癌肝移植受者中的使用目前仍未形成共识，包括靶向及免疫治疗使用的指征、时机及剂量等。本文对肝癌肝移植手术前后靶向及免疫治疗的指征及时机等展开综述，阐述相关临床进展，旨在为改善肝癌肝移植受者的生存提供参考。
- 肝细胞癌 /
- 肝移植 /
- 靶向治疗 /
- 免疫治疗 /
- 抗血管生成靶向药物（AATD） /
- 免疫检查点抑制剂（ICI） /
- 经导管动脉化疗栓塞（TACE） /
- 立体定向放射治疗 /
- 射频消融
Abstract: Liver transplantation is one of the main treatments of early hepatocellular carcinoma (HCC). The recurrence of HCC after liver transplantation severely affects the long-term survival rate of the recipients. Targeted therapy and immunotherapy play a critical role in HCC downstaging, preventing disease progression, reducing recurrence rate, prolonging the survival and improving the quality of life. However, no consensus has been reached on the application of targeted therapy and immunotherapy in recipients undergoing liver transplantation for HCC, including indications, timing and dosage. In this article, clinical research progresses on the indications and timing of targeted therapy and immunotherapy before and after liver transplantation for HCC were reviewed, aiming to provide reference for prolonging the survival of recipients after liver transplantation for HCC.
- Hepatocellular carcinoma /
- Liver transplantation /
- Targeted therapy /
- Immunotherapy /
- Antiangiogenic targeted drug (AATD) /
- Immune checkpoint inhibitor (ICI) /
- Transcatheter arterial chemoembolization (TACE) /
- Stereotactic radiotherapy /
- Radiofrequency ablation

HTML全文

下载: 全尺寸图片幻灯片

参考文献(57)

[1]	DE'ANGELIS N, LANDI F, CARRA MC, et al. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review[J]. World J Gastroenterol, 2015, 21(39): 11185-11198. DOI: 10.3748/wjg.v21.i39.11185.
[2]	BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/SLA.0000000000001894.
[3]	MEI J, LI SH, WANG QX, et al. Resection vs. sorafenib for hepatocellular carcinoma with macroscopic vascular invasion: a real world, propensity score matched analytic study[J]. Front Oncol, 2020, 10: 573. DOI: 10.3389/fonc.2020.00573.
[4]	KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
[5]	YU WC, ZHANG KZ, CHEN SG, et al. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study[J]. Medicine (Baltimore), 2018, 97(3): e9704. DOI: 10.1097/MD.0000000000009704.
[6]	QIN S, LI Q, GU S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568. DOI: 10.1016/S2468-1253(21)00109-6.
[7]	QIN S, BI F, GU S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011. DOI: 10.1200/JCO.21.00163.
[8]	ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
[9]	LEE MJ, CHANG SW, KIM JH, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea[J]. Invest New Drugs, 2021, 39(1): 260-268. DOI: 10.1007/s10637-020-00977-4.
[10]	OGASAWARA S, OOKA Y, ITOKAWA N, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan[J]. Invest New Drugs, 2020, 38(1): 172-180. DOI: 10.1007/s10637-019-00801-8.
[11]	GAO Q, ANWAR IJ, ABRAHAM N, et al. Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors[J]. Cancers (Basel), 2021, 13(24): 6307. DOI: 10.3390/cancers13246307.
[12]	ZIOGAS IA, EVANGELIOU AP, GIANNIS D, et al. The role of immunotherapy in hepatocellular carcinoma: a systematic review and pooled analysis of 2, 402 patients[J]. Oncologist, 2021, 26(6): e1036-e1049. DOI: 10.1002/onco.13638.
[13]	QIN S, REN Z, MENG Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470-2045(20)30011-5.
[14]	DUCREUX M, ABOU-ALFA G, REN Z, et al. Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma[J]. Ann Oncol, 2021, 32(S3): S217. DOI: 10.1016/j.annonc.2021.05.005.
[15]	DAI L, CAI X, MUGAANYI J, et al. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 19711. DOI: 10.1038/s41598-021-98937-2.
[16]	ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
[17]	FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[18]	CHENG AL, QIN S, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76(4): 862-873. DOI: 10.1016/j.jhep.2021.11.030.
[19]	FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.
[20]	HAN C, YE S, HU C, et al. Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase Ib/Ⅱ trial (AK105-203)[J]. Front Oncol, 2021, 11: 684867. DOI: 10.3389/fonc.2021.684867.
[21]	ZHANG W, BI X, SUN Y, et al. Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: a phase Ib study[J]. J Clin Oncol, 2020, 38(15_suppl): 3079. DOI: 10.1200/JCO.2020.38.15_suppl.3079.
[22]	XIE D, SUN Q, WANG X, et al. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world[J]. Ann Transl Med, 2021, 9(8): 652. DOI: 10.21037/atm-20-7037.
[23]	REN Z, XU J, BAI Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7.
[24]	XU J, SHEN J, GU S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078-0432.CCR-20-2571.
[25]	张雯雯, 胡丙洋, 韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 26(12): 947-948. DOI: 10.3760/cma.j.cn113884-20201203-00611. ZHANG WW, HU BY, HAN J, et al. Preliminary report on the study of conversion therapy of advanced hepatocellular carcinoma combined PD-1 inhibitors with multi-target tyrosine kinase inhibitors[J]. Chin J Hepatobiliary Surg, 2020, 26(12): 947-948. DOI: 10.3760/cma.j.cn113884-20201203-00611.
[26]	中国医师协会肝癌专业委员会. 肝细胞癌免疫治疗中国专家共识(2021版)[J]. 中华医学杂志, 2021, 101(48): 3921-3931. DOI: 10.3760/cma.j.cn112137-20210817-01855. Chinese Sociaty of Liver Cancer, Chinese Medical Doctor Association. Chinese expert consensus on immunotherapy for hepatocellular carcinoma (2021 edition)[J]. Natl Med J China, 2021, 101(48): 3921-3931. DOI: 10.3760/cma.j.cn112137-20210817-01855.
[27]	CHEN DS, MELLMAN I. Oncology meets immunology: the cancer-immunity cycle[J]. Immunity, 2013, 39(1): 1-10. DOI: 10.1016/j.immuni.2013.07.012.
[28]	FERRARA N, HILLAN KJ, GERBER HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer[J]. Nat Rev Drug Discov, 2004, 3(5): 391-400. DOI: 10.1038/nrd1381.
[29]	KERMICHE-RAHALI S, DI FIORE A, DRIEUX F, et al. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib[J]. World J Surg Oncol, 2013, 11(1): 171. DOI: 10.1186/1477-7819-11-171.
[30]	中华预防医学会肝胆胰疾病预防与控制专业委员会, 中国抗癌协会肝癌专业委员会, 北京医学会外科学分会肝脏学组, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J/CD]. 肝癌电子杂志, 2021, 8(2): 6-15. DOI: 10.3969/j.issn.2095-7815.2021.02.004. Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer of Chinese Anti-Cancer Association, Liver Study Group of Surgery Committee of Beijing Medical Association, et al. Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 edition)[J/CD]. Electr J Liver Tumor, 2021, 8(2): 6-15. DOI: 10.3969/j.issn.2095-7815.2021.02.004.
[31]	樊嘉, 高强. 肝癌的免疫治疗: 有希望便是光明[J]. 中华消化外科杂志, 2022, 21(2): 199-204. DOI: 10.3760/cma.j.cn115610-20220215-00080. FAN J, GAO Q. Immunotherapy for hepacellular carcinoma: where there is hope, there is brightness[J]. Chin J Dig Surg, 2022, 21(2): 199-204. DOI: 10.3760/cma.j.cn115610-20220215-00080.
[32]	王俊洁, 徐龙, 袁国盛, 等. 信迪利单抗联合仑伐替尼二线治疗不可切除肝细胞肝癌的临床疗效及安全性[J]. 实用医学杂志, 2022, 38(9): 1130-1135. DOI: 10.3969/j.issn.1006-5725.2022.09.016. WANG JJ, XU L, YUAN GS, et al. Efficacy and safety of sintilimab in combination with lenvatinib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma[J]. J Pract Med, 2022, 38(9): 1130-1135. DOI: 10.3969/j.issn.1006-5725.2022.09.016.
[33]	梁秀菊, 刘晓, 郑桂丽, 等. 免疫联合抗血管生成靶向一线治疗晚期肝癌的临床疗效[J]. 中华消化外科杂志, 2021, 20(S2): 15-19. DOI: 10.3760/cma.j.cn115610-20210628-00316. LIANG XJ, LIU X, ZHENG GL, et al. Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma[J]. Chin J Dig Surg, 2021, 20(S2): 15-19. DOI: 10.3760/cma.j.cn115610-20210628-00316.
[34]	CHERNYAK V, FOWLER KJ, KAMAYA A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients[J]. Radiology, 2018, 289(3): 816-830. DOI: 10.1148/radiol.2018181494.
[35]	KARDASHIAN A, FLORMAN SS, HAYDEL B, et al. Liver transplantation outcomes in a u. s. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond Milan criteria[J]. Hepatology, 2020, 72(6): 2014-2028. DOI: 10.1002/hep.31210.
[36]	CHAPMAN WC, GARCIA-AROZ S, VACHHARAJANI N, et al. Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions[J]. J Am Coll Surg, 2017, 224(4): 610-621. DOI: 10.1016/j.jamcollsurg.2016.12.020.
[37]	SAAB S, MCTIGUE M, FINN RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy[J]. Exp Clin Transplant, 2010, 8(4): 307-313.
[38]	EILARD MS, ANDERSSON M, NAREDI P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation[J]. BMC Cancer, 2019, 19(1): 568. DOI: 10.1186/s12885-019-5760-8.
[39]	李照, 朱继业. 免疫治疗时代下的肝癌肝移植[J]. 临床肝胆病杂志, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001. LI Z, ZHU JY. Liver transplantation for liver cancer in the era of immunotherapy[J]. J Clin Hepatol, 2021, 37(2): 249-252. DOI: 10.3969/j.issn.1001-5256.2021.02.001.
[40]	汪国营. 肝癌肝移植相关热点问题探讨[J]. 中山大学学报(医学科学版), 2021, 42(1): 17-23. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK202101003.htm WANG GY. Hot issues related to liver transplantation for hepatocellular carcinoma[J]. J Sun Yat-sen Univ (Med Sci), 2021, 42(1): 17-23. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK202101003.htm
[41]	QIAO ZY, ZHANG ZJ, LV ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: a cohort study and literature review[J]. Front Immunol, 2021, 12: 653437. DOI: 10.3389/fimmu.2021.653437.
[42]	CENTANNI M, MOES DJAR, TROCóNIZ IF, et al. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors[J]. Clin Pharmacokinet, 2019, 58(7): 835-857. DOI: 10.1007/s40262-019-00748-2.
[43]	SPAIN L, DIEM S, LARKIN J. Management of toxicities of immune checkpoint inhibitors[J]. Cancer Treat Rev, 2016, 44: 51-60. DOI: 10.1016/j.ctrv.2016.02.001.
[44]	SHI GM, WANG J, HUANG XW, et al. Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors[J]. Liver Transpl, 2021, 27(3): 444-449. DOI: 10.1002/lt.25887.
[45]	NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617.
[46]	CHEN GH, WANG GB, HUANG F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66: 101386. DOI: 10.1016/j.trim.2021.101386.
[47]	JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7): 932-945. DOI: 10.1002/lt.25191.
[48]	HAN B, DING H, ZHAO S, et al. Potential role of adjuvant lenvatinib in improving disease-free survival for patients with high-risk hepatitis B virus-related hepatocellular carcinoma following liver transplantation: a retrospective, case control study[J]. Front Oncol, 2020, 10: 562103. DOI: 10.3389/fonc.2020.562103.
[49]	SARICI B, ISIK B, YILMAZ S. Management of recurrent HCC after liver transplantation[J]. J Gastrointest Cancer, 2020, 51(4): 1197-1199. DOI: 10.1007/s12029-020-00498-6.
[50]	KANG SH, CHO H, CHO EJ, et al. Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence[J]. J Korean Med Sci, 2018, 33(45): e283. DOI: 10.3346/jkms.2018.33.e283.
[51]	DE'ANGELIS N, LANDI F, NENCIONI M, et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Prog Transplant, 2016, 26(4): 348-355. DOI: 10.1177/1526924816664083.
[52]	TOSO C, MENTHA G, MAJNO P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence[J]. J Hepatol, 2013, 59(1): 3-5. DOI: 10.1016/j.jhep.2013.03.029.
[53]	LI Z, GAO J, ZHENG S, et al. Therapeutic efficacy of sorafenib in patients with hepatocellular carcinoma recurrence after liver transplantation: a systematic review and Meta-analysis[J]. Turk J Gastroenterol, 2021, 32(1): 30-41. DOI: 10.5152/tjg.2020.19877.
[54]	CHEN YY, CHEN CL, LIN CC, et al. Efficacy and safety of lenvatinib in hepatocellular carcinoma patients with liver transplantation: a case-control study[J]. Cancers (Basel), 2021, 13(18): 4584. DOI: 10.3390/cancers13184584.
[55]	IAVARONE M, INVERNIZZI F, CZAUDERNA C, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation[J]. Am J Transplant, 2019, 19(11): 3176-3184. DOI: 10.1111/ajt.15551.
[56]	DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6): 1054-1062. DOI: 10.21037/jgo.2018.07.05.
[57]	GASSMANN D, WEILER S, MERTENS JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research[J]. Transplant Direct, 2018, 4(8): e376. DOI: 10.1097/TXD.0000000000000814.